title: Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
abstract: BACKGROUND
  Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects.
  
  
  OBJECTIVE
  To compare two different regimens of rabeprazole-based triple therapy vs. 7-day omeprazole-based triple therapy for the eradication of Helicobacter pylori infection.
  
  
  METHODS
  Patients with proven H. pylori infection were randomized to receive: (i) 7-day rabeprazole, 10 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; (ii) 3-day rabeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; or (iii) 7-day omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily. Endoscopy (CLO test, histology) was performed before randomization and 6 weeks after drug treatment.
  
  
  RESULTS
  One hundred and seventy-three patients were randomized. H. pylori eradication rates (intention-to-treat, n=173/per protocol, n=167) were 88%/91% for 7-day rabeprazole-based therapy, 72%/72% for 3-day rabeprazole-based therapy and 82%/89% for 7-day omeprazole-based therapy, respectively. The per protocol eradication rate was significantly better in the 7-day rabeprazole-based therapy and 7-day omeprazole-based therapy groups when compared to the 3-day rabeprazole-based therapy group (P=0.01 and P=0.04, respectively). Compliance was excellent and all three regimens were well tolerated.
  
  
  CONCLUSIONS
  The efficacy of seven-day rabeprazole-based triple therapy is similar to 7-day omeprazole-based triple therapy for the eradication of H. pylori infection.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong. bcywong@hku.hk
authors.forename: B C
authors.initials: BC
authors.lastname: Wong
authors.forename: W M
authors.initials: WM
authors.lastname: Wong
authors.forename: Y K
authors.initials: YK
authors.lastname: Yee
authors.forename: W K
authors.initials: WK
authors.lastname: Hung
authors.forename: A W
authors.initials: AW
authors.lastname: Yip
authors.forename: M L
authors.initials: ML
authors.lastname: Szeto
authors.forename: K F
authors.initials: KF
authors.lastname: Li
authors.forename: P
authors.initials: P
authors.lastname: Lau
authors.forename: F M
authors.initials: FM
authors.lastname: Fung
authors.forename: T S
authors.initials: TS
authors.lastname: Tong
authors.forename: K C
authors.initials: KC
authors.lastname: Lai
authors.forename: W H
authors.initials: WH
authors.lastname: Hu
authors.forename: M F
authors.initials: MF
authors.lastname: Yuen
authors.forename: C K
authors.initials: CK
authors.lastname: Hui
authors.forename: S K
authors.initials: SK
authors.lastname: Lam
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000517:prevention & control; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use*; D006180:Proton-Translocating ATPases / Q000037:antagonists & inhibitors; D064750:Rabeprazole; D013276:Stomach Ulcer / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D064750:Rabeprazole; D006180:Proton-Translocating ATPases; D009853:Omeprazole